CRH Stimulation Test Boosts Cushing Disease Diagnosis CRH Stimulation Test Boosts Cushing Disease Diagnosis
Running a corticotropin-releasing hormone stimulation test after a dexamethasone suppression test enhanced Cushing disease diagnosis, but with one additional false positive.First Look (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 21, 2022 Category: Endocrinology Tags: Internal Medicine News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL High-Dose MTX Does Not Reduce CNS Relapse in Pediatric ALL
The UKALL2011 study also showed that a shorter course of dexamethasone did not reduce toxicities, and that monthly pulses of vincristine/dexamethasone don ' t reduce bone marrow relapse.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Assessing medication use patterns in patients hospitalised with COVID-19: a retrospective study
Scottish study (n=4,063) found use of adjuvant medicines in patients hospitalised with COVID-19 was in line with evolving evidence and changing treatment guidelines, with 81.4% and 17.8% treated with 1 or 2 medicines; and dexamethasone monotherapy accounting for majority (76.2%). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 7, 2022 Category: Consumer Health News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma
(MedPage Today) -- Combination treatment with belantamab mafodotin (belamaf; Blenrep) plus lenalidomide (Revlimid) and dexamethasone appeared effective for relapsed or refractory multiple myeloma, and had a tolerable safety profile, according to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2022 Category: Hematology Source Type: news
Preventing Doxorubicin-Induced Hand-Foot Syndrome Preventing Doxorubicin-Induced Hand-Foot Syndrome
Dexamethasone plus wrist and ankle cooling may prevent hand-foot syndrome from doxorubicin in patients with ovarian cancer. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 27, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Attempted suicide, dexamethasone, and COVID-19: Clinical Case on COVID-19 treatments and the implications for mental health - Plasencia-Garc ía BO, García-Ligero E, Menéndez IE, Gotor F, González-Fuentes Y, Crespo-Facorro B.
The World Health Organization (WHO) declared the outbreak of coronavirus 2019 (COVID-19) a public health emergency on January 30, 2020.1 Corticosteroids (not used in previous epidemics of severe respiratory syndromes due to risk of worsening lung lesion... (Source: SafetyLit)
Source: SafetyLit - September 10, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Janssen Marks First Approval Worldwide for TECVAYLI ® (teclistamab) with EC Authorisation of First-in-Class Bispecific Antibody for the Treatment of Patients with Multiple Myeloma
BEERSE, BELGIUM, August 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI® (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). Patients must have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.[1] Today’s milestone marks the first approval worldwide for teclistamab, a first-i...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Survival Benefit With Triple Therapy for Severe COVID-19
THURSDAY, Aug. 11, 2022 -- For patients with severe COVID-19 requiring high flow nasal cannula (HFNC), triple therapy of dexamethasone, remdesivir, and baricitinib is associated with significant survival benefit compared with dual therapy, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 11, 2022 Category: Pharmaceuticals Source Type: news
Janssen Receives Positive CHMP Opinion for Novel Bispecific Antibody TECVAYLI ® (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma (RRMM)
BEERSE, Belgium, 22 July 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation (CMA) for TECVAYLI® (teclistamab) as monotherapy for adult patients with relapsed and refractory multiple myeloma (RRMM), who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. Teclistamab is an off-the-shelf, T-cell r...
Source: Johnson and Johnson - July 22, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Study Compares Baricitinib to Dexamethasone for COVID-19
TUESDAY, June 21, 2022 -- For hospitalized patients with COVID-19 requiring supplemental oxygen, baricitinib plus remdesivir and dexamethasone plus remdesivir result in similar mechanical ventilation-free survival by day 29, but adverse events occur... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 21, 2022 Category: Pharmaceuticals Source Type: news
Ivermectin for preventing and treating COVID-19
Is ivermectin effective for COVID ‐19? Updated Cochrane review'Ivermectin for preventing and treating COVID ‐19 'Key messagesWe found no evidence to support the use of ivermectin for treating COVID ‐19 or preventing SARS‐CoV‐2 infection. The evidence base improved slightly in this update, but is still limited.Evaluation of ivermectin is continuing in 31 ongoing trials, and we will update this review again when their results become available. What is ivermectin?Ivermectin is a medicine used to treat parasites, such as intestinal parasites in animals, and scabies in humans. It is inexpensive and is widely used in...
Source: Cochrane News and Events - June 21, 2022 Category: Information Technology Authors: Katie Abbotts Source Type: news
